Modeling Huntington's disease : An insight on in-vitro and in-vivo models
Copyright © 2023 Elsevier B.V. All rights reserved..
Huntington's disease is a neurodegenerative illness that causes neuronal death most extensively within the basal ganglia. There is a broad class of neurologic disorders associated with the expansion of polyglutamine (polyQ) repeats in numerous proteins. Several other molecular mechanisms have also been implicated in HD pathology, including brain-derived neurotrophic factor (BDNF), mitochondrial dysfunction, and altered synaptic plasticity in central spiny neurons. HD pathogenesis and the effectiveness of therapy approaches have been better understood through the use of animal models. The pathological manifestations of the disease were reproduced by early models of glutamate analog toxicity and mitochondrial respiration inhibition. Because the treatments available for HD are quite limited, it is important to have a definite preclinical model that mimics all the aspects of the disease. It can be used to study mechanisms and validate candidate therapies. Although there hasn't been much success in translating animal research into clinical practice, each model has something special to offer in the quest for a deeper comprehension of HD's neurobehavioral foundations. This review provides insight into various in-vitro-and in-vivo models of HD which may be useful in the screening of newer therapeutics for this incapacitating disorder.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 2023 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:459 |
|---|---|
| Enthalten in: |
Behavioural brain research - 459(2023) vom: 29. Feb., Seite 114757 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rana, Nitasha [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Excitotoxic lesion |
|---|
| Anmerkungen: |
Date Completed 25.12.2023 Date Revised 27.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.bbr.2023.114757 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364443405 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364443405 | ||
| 003 | DE-627 | ||
| 005 | 20231229124159.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.bbr.2023.114757 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1241.xml |
| 035 | |a (DE-627)NLM364443405 | ||
| 035 | |a (NLM)37952684 | ||
| 035 | |a (PII)S0166-4328(23)00475-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rana, Nitasha |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Modeling Huntington's disease |b An insight on in-vitro and in-vivo models |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.12.2023 | ||
| 500 | |a Date Revised 27.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier B.V. All rights reserved. | ||
| 520 | |a Huntington's disease is a neurodegenerative illness that causes neuronal death most extensively within the basal ganglia. There is a broad class of neurologic disorders associated with the expansion of polyglutamine (polyQ) repeats in numerous proteins. Several other molecular mechanisms have also been implicated in HD pathology, including brain-derived neurotrophic factor (BDNF), mitochondrial dysfunction, and altered synaptic plasticity in central spiny neurons. HD pathogenesis and the effectiveness of therapy approaches have been better understood through the use of animal models. The pathological manifestations of the disease were reproduced by early models of glutamate analog toxicity and mitochondrial respiration inhibition. Because the treatments available for HD are quite limited, it is important to have a definite preclinical model that mimics all the aspects of the disease. It can be used to study mechanisms and validate candidate therapies. Although there hasn't been much success in translating animal research into clinical practice, each model has something special to offer in the quest for a deeper comprehension of HD's neurobehavioral foundations. This review provides insight into various in-vitro-and in-vivo models of HD which may be useful in the screening of newer therapeutics for this incapacitating disorder | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Excitotoxic lesion | |
| 650 | 4 | |a Huntingtin | |
| 650 | 4 | |a Huntington’s disease | |
| 650 | 4 | |a Knock-in | |
| 650 | 4 | |a Polyglutamine | |
| 650 | 4 | |a Quinolinic acid | |
| 650 | 7 | |a Huntingtin Protein |2 NLM | |
| 700 | 1 | |a Kapil, Lakshay |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Charan |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Arti |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Behavioural brain research |d 1993 |g 459(2023) vom: 29. Feb., Seite 114757 |w (DE-627)NLM012632252 |x 1872-7549 |7 nnns |
| 773 | 1 | 8 | |g volume:459 |g year:2023 |g day:29 |g month:02 |g pages:114757 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.bbr.2023.114757 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 459 |j 2023 |b 29 |c 02 |h 114757 | ||